Clinical trial · Observational
Circulating Tumor Cells in Solid Tumors
Quantification and Characterization of Circulating Tumor Cells in Solid Tumors
NCT03161821CI-TRIAL-00061111completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to identify circulating tumor cells in patients with solid tumors. Quantify and characterize these cells, collect patient information in regards to the patient's cancer. Develop a database and a sample repository where future analysis could be done.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Solid Tumor, Adult | Adult Solid Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Observational | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (2)
- measure
- Documentation of the Quality of CTCs from Patients with Solid Tumors
- timeFrame
- Through study completion, an average of 5 years
- description
- Enumeration of participants' circulating solid tumor cells
- measure
- Documentation of the Characterization of CTCs from Patients with Solid Tumors
- timeFrame
- Through study completion, an average of 5 years
- description
- Characterization of participants' circulating solid tumor cells
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years of age * Biopsy proven solid tumor malignancy * Seen at UNC Chapel Hill Hospital and Health Care System * Consents to abstraction of their medical records * Signed an institutional review board (IRB)-approved informed consent document for this protocol Exclusion Criteria: * \< 18 years of age * Dementia, altered mental status, incarceration or any psychiatric condition that would prohibit the understanding or rendering of informed consent.
References
Publications (1)
- DERIVEDChera BS, Kumar S, Shen C, Amdur R, Dagan R, Green R, Goldman E, Weiss J, Grilley-Olson J, Patel S, Zanation A, Hackman T, Blumberg J, Patel S, Thorp B, Weissler M, Yarbrough W, Sheets N, Mendenhall W, Tan XM, Gupta GP. Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer. J Clin Oncol. 2020 Apr 1;38(10):1050-1058. doi: 10.1200/JCO.19.02444. Epub 2020 Feb 4. PMID 32017652